Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-219M in chemotherapy-induced thrombocytopenia
NCT05426369Phase 1Active, not recruiting
- Sponsor
- Clover Biopharmaceuticals
- Start
- Jun 2022
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCB-219 in chemotherapy-induced thrombocytopenia (CIT) (3 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Occurrence of Dose-Limiting Toxicity at 21 days, Frequency of Dose-Limiting Toxicity at 21 days and 1 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
SCB-219
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05426369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426369.